Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
12 Apr, 2019 (Friday)



ESSEX BIO-TECH(1061)
Analysis:
ESSEX BIO-TECH is a leading ophthalmology and surgical drug manufacturer and promoter in China. Driven by the core patent drug bFGF, the company`s five-year revenue CAGR has increased by more than 20% annually, and the profit CAGR more than 30% annually. Since the launch of the “Enhancement Plan” in 2015, the company has successfully invested in different targets and cooperated in various markets. Recently, the company signed an agreement with Russian Mitotech to obtain the permanent commercialization rights of its third-phase clinical dry eye products in Singapore and Greater China at a price of up to US$37 million, while sharing global benefits. In addition, ESSEX BIO-TECH recently invested 8% stake in the company "Shanggong Yixin", which focuses on fundus screening and chronic disease management and has an AI fundus screening products "Huiyantangwang". In addition, the company recently launched the first single-dose levofloxacin eye drop product without preservatives.
Strategy:
Buy-in Price: $6.50, Target Price: $8.00, Cut Loss Price: $5.70


Topcon Corporation(7732.JT)
Founded in 1932, Topcon Corporation manufactures and sells measuring equipment (GPS) and medical equipment primarily for ophthalmologist use. The Company also manufactures industrial products including projectors and optical devices. . For its earnings report of first three quarters of 2019 fiscal year announced on 30th January, 2019, the year over year growth of revenue & operating income of Topcon Corporation was 1.4% (¥163.1 billion) and 8.5% (¥6.76 billion). However, its net income decreased by 14.5% to¥ 2.52 billion. Due to the surge in demand for iConstruction and domestic IT agricultural products, the operating income from smart infrastructure and medical devices for ophthalmology increased 46.7 % and 8.5% respectively. For its full-year earning guidance, the revenue, operating income and net income of Topcon Corporation are expected to rise 3.1% to ¥150 billion, 24.2% to ¥15 billion and, 16.1% to ¥7 billion year over year respectively. Despite the ICT automation construction business affected by slowdown of US construction and agricultural industries, the mid- and long-term growth forecast are still maintained. In addition, the smart infrastructure development is part of Japan's “National Strengthening Program”, while the growth of the ophthalmology business in the Chinese health care market is highly anticipated. Recommend to buy at ¥1405, target price ¥1519, cut loss if drop below ¥1312.



Air China (753.HK) - 18Q4 Result Beat

Investment Summary

The 18Q4 Result Turns from Loss and the Year-round Net Profit Is Basically Flat Which Is Better than Expected

Air China reported revenues of RMB136.77 billion in 2018, up by 12.7% yoy. The net profit attributable to parent company was RMB7.34 billion, up by 1.3% yoy. Its EPS was RMB0.53 basically, down by 1.85% yoy due to the dilution of A share's private placement. Dividend per share was RMB0.1033, with the dividend rate of 19.5%.

The result of Air China in the 2018Q4 was better than expected, turning from a loss of RMB1.04 billion in the same period last year to a profit of RMB399 million. It was the main force to stop the downs and maintain the flat in the whole year (the net profit of the company in the first three quarters fell 16% yoy). We believe the main reason making the fourth-quarter result better than expected are:

1) Revenue: due to the market-oriented increase in ticket prices for key routes and the company's optimization strategy for capacity allocation, the Air China's RPK increased by 6% in the fourth quarter yoy, while its revenue rose largely by 14.6%.

2) Cost: although the fuel cost price increased by 35% yoy, the financial expense increased RMB767 million due to the devaluation of RMB. The operating costs increased by 13.1% yoy due to the good cost control, which was less than revenue growth.

3) The results of affiliated business turned well, which increased the investing revenue by RMB450 million, and other revenue and non-operating revenue increased by RMB655 million annually.

The 2018FY Result Is Under Pressure of the Rising Oil Prices and the Exchange Losses

The result of Air China's cost was still significantly depressed due to the oil prices and exchange in the whole 2018. The fuel cost increased by 35.5% (or RMB10.07 billion) yoy. The exchange loss recorded RMB2.38 billion, while it recorded a profit of RMB2.94 billion in the same period last year. Fortunately, the market-oriented increase in ticket prices, the structure optimization of aircraft allocation under the control of transport capacity, cost control and other measures improved the company's profitability of its main business. The revenue of RPK and unit freight per ATK increased by 2.9% and 5.4% to RMB0.5461 and RMB1.4312, respectively.

In addition, because the result of Cathay Pacific turned from loss to profit. The Company recognized the investing incoming of RMB202 million, and the losses in the same period of last year was RMB986 million.

At the end of the period, the Company's asset-liability ratio decreased by 1 ppts to 58.75%. The cash and cash equivalents reached RMB6.76 billion, accounting for 28% of current assets. The proportion of dollar liability in interest-bearing debts continued to decline from 41% on the end 2017 to 30%.

The Trend of Tight Balance between Supply and Demand Is More Obvious and The External Conditions Are Generally Positive in 2019

From the perspective of transport capacity in the industry, in order to ensure the punctuality rate of flights and the safety of aviation, the regulatory authorities still maintained strict control over the time limits of civil aviation resources. However, the grounding of Boeing 737MAX aggravated the trend of further contraction of industry supply. The May Day holiday and Beijing International Horticultural Exposition this year will have a positive pulling effect on aviation demand. Under the circumstance of tight balance between supply and demand, the prosperity of the industry is expected to continue to rise.

At present, the international oil price has fallen sharply compared with the same period, and the pressure of fuel cost of aviation enterprises has been greatly alleviated. The trend of rapid depreciation of RMB has been curbed. And Air China's dollar liabilities have fallen to 30%, and flexibility of exchange rate has continued to drop.

Valuation & Investment thesis

According to the latest hypothesis of the oil cost and exchange rate, we revised our estimate 2019/2020 net profit of AC to be 11.18/12.92 billion RMB. The target price is adjusted to HKD11, estimates 12.7/11x P/E and 1.38/1.26x P/B in 2019/2020. “Accumulate” rating is given. (Closing price as at 9 April 2019)

Risk

Traffic demand languished for the deterioration of macro-economy;

The depreciation of the RMB against USD would bring exchange loss;

Oil prices rose exceeded forecast.

War, terrorist attacks, SARS and other emergencies;

Highspeed railway diversion

Financials

Click Here for PDF format...




Recommendation on 12-4-2019
RecommendationAccumulate
Price on Recommendation Date$ 10.240
Suggested purchase priceN/A
Target Price$ 11.000
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.